PMID- 1953529
OWN - NLM
STAT- MEDLINE
DCOM- 19911127
LR  - 20190824
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 21
IP  - 4
DP  - 1991 Aug
TI  - Chronic myeloid leukaemia treated by allogeneic bone marrow transplantation from 
      histocompatible sibling donors--an invariably fatal malignancy rendered highly 
      curable.
PG  - 408-13
AB  - Twenty-eight patients aged 16-50 years with chronic myeloid leukaemia (CML) 
      underwent allogeneic bone marrow transplantation (BMT) using human leukocyte 
      antigen (HLA)-identical sibling donors. Of the 28 patients, 21 were in chronic 
      phase, five were in accelerated phase and two were in blast phase at the time of 
      BMT. Twenty-three of the patients survived more than 63-2187 days after BMT, 21 
      in continuous complete remission and two with haematologic relapse of CML. Two 
      patients died of interstitial pneumonitis and one died of relapsed CML, cerebral 
      aspergillosis and cytomegalovirus enterocolitis. The overall probability of 
      survival at six years was 78% +/- 9% (mean +/- standard error) and of disease 
      free survival 66 +/- 11%. For patients transplanted in chronic phase, the 
      survival probability was 90 +/- 6%, while all of the patients undergoing BMT in 
      chronic phase within the first year after diagnosis were alive with a 
      relapse-free survival of 88 +/- 12%. The actuarial probability of occurrence of 
      acute graft-versus-host disease (GVHD) was 57 +/- 9%, while for Grades II and III 
      GVHD it was 28 +/- 9%. Chronic GVHD occurred in 18 of 25 patients at risk. The 
      majority of patients had a Karnofsky performance score at latest follow-up of at 
      least 90% (range 50-100). We conclude that allogeneic BMT is effective, curative 
      therapy for CML and that BMT performed earlier in the natural history of the 
      disease is associated with the best outcome.
FAU - Szer, J
AU  - Szer J
AD  - Clinical Haematology and Bone Marrow Transplantation Unit, Alfred Hospital, 
      Melbourne, VIC, Australia.
FAU - Sheridan, W P
AU  - Sheridan WP
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Bone Marrow Transplantation/adverse effects
MH  - Graft vs Host Disease
MH  - HLA Antigens/*analysis
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality/*surgery
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Preoperative Care
MH  - Survival Rate
MH  - *Tissue Donors
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1991.tb01340.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1991 Aug;21(4):408-13. doi: 10.1111/j.1445-5994.1991.tb01340.x.